Feels as though BQE has moved too far too quickly to me. Although they are expected to exceed market expectations they will now need a massive profit increase to warrent a market cap of £123m. Not sure where all the extra turnover will come from to generate this as their products are very specialised and certanly not for NHS/ mass market.
Assuming you're talking about Bioquell (LON:BQE)
I agree, I think the valuation has gotten a little ahead of itself and even the recurring revenue element of sales isn't enough to convince me to buy back in at this price.
Appears to be a good business though, with cash generation and international exposure
